Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | HPN217 |
Synonyms | |
Therapy Description |
HPN217 is a tri-specific molecule that targets BCMA (TNFRSF17) and CD3 epsilon domain (CD3e), as well as human serum albumin, which potentially results in activation of T-cell response and increased death of BCMA-expressing tumor cells (Blood (2018) 132 (Supplement 1): 3225). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
HPN217 | HPN-217|TriTAC HPN 217|Anti-BCMA/CD3e TriTAC HPN217 | CD3 Antibody 99 TNFRSF17 Antibody 20 | HPN217 is a tri-specific molecule that targets BCMA (TNFRSF17) and CD3 epsilon domain (CD3e), as well as human serum albumin, which potentially results in activation of T-cell response and increased death of BCMA-expressing tumor cells (Blood (2018) 132 (Supplement 1): 3225). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT04184050 | Phase Ib/II | HPN217 | A Phase 1/2 Open-label, Multicenter, Dose Escalation and Dose Expansion Study of the Safety, Tolerability, and PK of HPN217 in Patients With R/R MM | Active, not recruiting | USA | FRA | ESP | 0 |